Emanuele Palomba

Scopus Publications

Correction: Integrating artificial intelligence with genome sequencing against antimicrobial resistance: a narrative review
Giovanni Scaglione, Nicolò Mastroianni, Alberto Rizzo, Emanuele Palomba, Davide Carcione, Sara Giordana Rimoldi, Gioconda Brigante, Luigi Principe, Marta Colaneri, Andrea Gori, Fabio Borgonovo
Frontiers in Public Health, 2026
[This corrects the article DOI: 10.3389/fpubh.2026.1757161.].
Gastritis and AIDS-related cholangiopathy as an unusual presentation of HIV infection
Fabio Brivio, Alice Covizzi, Davide Bernasconi, Guido Gubertini, Monica Schiavini, Silvia Grosso, Luca Carsana, Massimo Tonolini, Manuela Nebuloni, Andrea Gori, Emanuele Palomba
Gastroenterology Report, 2026
Ventilator-Associated Pneumonia Due to ESBL-Producing Escherichia coli Successfully Treated with Cefepime/Enmetazobactam: A European Case Report
Bruno Viaggi, Tommaso Giani, Emanuele Palomba, Andrea Gori, Alberto Farese, Gian Maria Rossolini, Marta Colaneri
Infectious Diseases and Therapy, 2026
Extended-spectrum β-lactamase (ESBL)-producing Enterobacterales represent a growing cause of ventilator- associated pneumonia (VAP) in critically ill patients. Although carbapenems remain the standard treatment, carbapenem-sparing strategies are increasingly needed to limit the emergence of carbapenem resistance. Cefepime/enmetazobactam (FEP/META) is a novel β-lactam/β-lactamase inhibitor combination with demonstrated activity against ESBL-producing organisms and favorable intrapulmonary pharmacokinetic properties. We present one of the first reported European cases of VAP due to CTX-M-producing Escherichia coli successfully treated with cefepime/enmetazobactam in a 72-year-old patient admitted to the intensive care unit for traumatic spinal cord injury. The isolate was resistant to third-generation cephalosporins and cefepime but remained susceptible to carbapenems and FEP/META (minimum inhibitory concentration [MIC] 0.06 mg/L). Targeted treatment with FEP/META (2.5 g every 8 h intravenously) was administered for 7 days. Rapid clinical and microbiological improvement was observed, with resolution of fever, decline in inflammatory biomarkers, and improvement in oxygenation parameters. No relapse or adverse events occurred. This case supports the potential role of FEP/META as a carbapenem-sparing option for ESBL-related VAP and highlights the importance of pharmacokinetic/pharmacodynamic considerations in optimizing antimicrobial stewardship strategies. Ventilator-associated pneumonia (VAP) is a serious lung infection that occurs in patients receiving mechanical ventilation in the intensive care unit. Some bacteria causing ventilator-associated pneumonia produce enzymes called extended-spectrum β-lactamases (ESBLs), which make them resistant to many commonly used antibiotics. Carbapenems are often used to treat these infections, but their widespread use may promote the development of further resistance. Cefepime/enmetazobactam is a new antibiotic combination designed to treat infections caused by ESBL-producing bacteria. We describe the case of a 72-year-old critically ill patient who developed ventilator-associated pneumonia caused by ESBL-producing Escherichia coli. The infection was successfully treated with cefepime/enmetazobactam without the need for carbapenem therapy. The patient improved rapidly and experienced no recurrence of infection. This report suggests that cefepime/enmetazobactam may represent an effective carbapenem-sparing treatment option for certain severe lung infections, although further clinical studies are needed.
Integrating artificial intelligence with genome sequencing against antimicrobial resistance: a narrative review
Giovanni Scaglione, Nicolò Mastroianni, Alberto Rizzo, Emanuele Palomba, Davide Carcione, Gioconda Brigante, Luigi Principe, Marta Colaneri, Andrea Gori, Fabio Borgonovo
Frontiers in Public Health, 2026
Antimicrobial resistance (AMR) represents an escalating global health threat, demanding diagnostic strategies capable of rapid, accurate, and comprehensive pathogen characterization. Genomic sequencing has transformed our ability to elucidate resistance mechanisms and track their evolution, yet its routine clinical adoption remains limited by cost, workflow constraints, and extended turnaround times. This narrative review examines how artificial intelligence (AI) and machine learning (ML) can enhance and operationalize sequencing-based diagnostics across the clinical microbiology continuum. We summarize current AI applications in whole-genome sequencing for AMR prediction, pan-genome feature extraction, and multicenter model generalizability, including emerging approaches such as federated learning. We then explore AI-driven metagenomic analytics for pathogen detection, resistome profiling, outbreak investigation, and prognostic modeling. Complementary non-genomic technologies, Raman spectroscopy and MALDI-TOF MS, are also evaluated for their potential to deliver rapid resistance profiling when integrated with ML. Finally, we discuss practical barriers, including cost, dataset standardization, interpretability, and regulatory challenges, while outlining future directions toward scalable, explainable, and equitable AI-guided diagnostics. Integrating AI with genomic and rapid phenotypic tools offers a pathway to real-time surveillance, optimized antimicrobial stewardship, and strengthened preparedness against emerging infectious threats.
Microbial signatures and host immune responses associated with the development of ventilator-associated pneumonia among patients with neurological injuries
Leonardo Mancabelli, Emanuele Palomba, Federico Magni, Liliane Chatenoud, Ilaria Olgiati, Chiara Buracchi, Cristina Bugarin, Giuseppe Gaipa, Chiara Abbruzzese, Matteo Filippini, Andrea Forastieri, Roberto Fumagalli, Federico Geraldini, Edoardo Picetti, Leonardo Terranova, Rosanna Vaschetto, Tommaso Zoerle, Marco Ventura, Giuseppe Citerio, Andrea Gori, Alessandra Bandera, Laura Alagna, Francesca Turroni
Microbiology Spectrum, 2026
Ventilator-associated pneumonia (VAP) remains a leading complication in mechanically ventilated patients, yet the contribution of the respiratory microbiota remains poorly understood. The PULMIVAP study is a multicenter, longitudinal cohort investigation of respiratory microbiota composition and host immune responses in critically ill adults intubated for non-pulmonary conditions. A total of 146 intubated adult patients were enrolled across eight Italian ICUs, forming matched groups of 73 with VAP and 73 without. Oropharyngeal swabs and endotracheal aspirates were collected at intubation and either at VAP diagnosis or at a matched point in controls for a total of 584 biological samples. Metataxonomic analyses revealed substantial temporal shifts in microbial communities across both upper and lower respiratory compartments, with a trend toward reduced microbial richness in patients who developed VAP. Several genera, such as Corynebacterium, were more abundant in no-VAP patients, whereas Escherichia-Shigella and Peptoniphilus were enriched in VAP samples. Cytokine-microbiota correlation analysis suggested a pro-inflammatory signature in VAP patients, with Citrobacter positively associated with IFN-γ and TNF-α, while several commensal genera were inversely correlated with inflammatory mediators. Additionally, taxa associated with VAP correlated with lower PaO 2 /FiO 2 ratios, implicating them in disease severity. Consistently, several bacteria, such as Corynebacterium , appeared to be linked to better respiratory outcomes, suggesting protective or risk-associated microbial profiles. Overall, these findings highlight the complex interplay between microbial communities and mucosal immunity in the pathogenesis of VAP. The identification of condition-associated microbial and immunological signatures may inform future strategies for risk stratification and targeted prevention. IMPORTANCE Ventilator-associated pneumonia (VAP) remains a major complication of mechanical ventilation, yet most microbiome studies have focused on late-stage infection or single airway compartments, limiting insight into early microbial dynamics associated with VAP risk. By longitudinally characterizing upper and lower airway microbiota before and during VAP development, this study provides new insights into microbial and immune patterns associated with susceptibility and disease severity in humans. These findings contribute to the current understanding of VAP pathogenesis by suggesting a role for early airway dysbiosis and local immune responses alongside clinical factors. Remarkably, the identification of taxa associated with risk or protection supports the potential for microbiota-informed monitoring and future risk stratification strategies during mechanical ventilation. CLINICAL TRIALS This study is registered with ClinicalTrials.gov as NCT04849039 .
Activity of imipenem/relebactam against KPC-producing Klebsiella pneumoniae and the possible role of Ompk36 mutation in determining resistance: an Italian retrospective analysis
Emanuele Palomba, Agnese Comelli, Francesca Saluzzo, Federico Di Marco, Elisa Matarazzo, Noemi Lo Re, Alessandra Bielli, Chiara Silvia Vismara, Antonio Muscatello, Marianna Rossi, Daniela Maria Cirillo, Alessandra Bandera, Andrea Gori
Annals of Clinical Microbiology and Antimicrobials, 2025
Antimicrobial resistance in Enterobacterales represents a substantial threat in modern clinical practice and the collection of data on the efficacy of new molecules is of paramount importance. Our study aimed to analyse the in vitro activity of imipenem/cilastatin/relebactam (IMI/REL) against KPC-producing Klebsiella pneumoniae (KPC-Kp) and investigate the genetic determinants of resistance to this agent. A total of 603 KPC-Kp strains, which were randomly collected during a multicentre study in northern Italy in the period 2016–2018, were analysed retrospectively. Antibiotic susceptibility testing was performed using a commercial broth microdilution. IMI-REL-resistant KPC-Kp strains were further analysed by whole genome sequencing to identify resistance determinants. Ninety-eight percent of KPC-Kp (591/603) showed in vitro susceptibility to IMI/REL, with a minimum inhibitory concentration below the EUCAST cut-off. Different mutations in OmpK36 were found in all 12 IMI/REL-resistant strains, which belonged to MLST STs 258 (3 isolates), 307 (8 isolates) and 512 (1 isolate), but no clonal relatedness was detected by the minimum spanning tree analysis, except for 2 strains isolated in the same hospital. Equal distribution of blaKPC−2 (6/12) and blaKPC−3 (6/12) was found, and in 11 isolates the presence of genetic variants associated with the production of beta-lactamases was also identified. KPC-Kp resistant to IMI/REL retained susceptibility to meropenem/vaborbactam (MVB, 12/12, 100%) and ceftazidime/avibactam (CZA, 11/12, 91.7%). Only one strain of 603 was resistant to either MVB and CZA but susceptible to IMI/REL with a MIC of 2 mg/L; 4/603 (0.7%) were resistant to CZA but susceptible to IMI/REL and MVB. IMI/REL showed good in vitro activity against the KPC-Kp strains analysed. All the IMI/REL-resistant strains displayed a mutation in porin OmpK36 and produced carbapenemases, with KPC-2 and KPC-3 being equally distributed. MVB and CZA maintained good activity against IMI/REL resistant isolates.
Hospital Acquired Infections Among Solid Organ Transplant Recipients Hospitalized in Intensive Care Unit (2018–2024): A Study of the GiViTI Group
Camilla Genovese, Martina Offer, Marta Colaneri, Francesca Dore, Giorgia Montrucchio, Giovanni Scaglione, Gianpaola Monti, Alessandra Bandera, Bruno Viaggi, Andrea Gori, Emanuele Palomba, Andrea Lombardi, Stefano Finazzi, and
Transplant Infectious Disease, 2025
Introduction Limited data exist regarding the burden of intensive care unit (ICU)‐acquired infections in the early post‐solid organ transplant (SOT) period, particularly in multidrug resistant organisms‐endemic settings. This study aims at describing the epidemiology, clinical characteristics, and outcomes of patients who developed an ICU‐acquired infection following a SOT procedure in Italy from 2018 to 2024. Methods A multicenter, retrospective study was conducted within the Italian PROSAFE project across 31 ICUs from 2018 to 2024. All adult patients admitted to ICU during the same hospitalization as their organ transplant procedure were included. Bloodstream infections, ventilator associated pneumonia, intra‐abdominal infections, and urinary tract infections occurring more than 48 h after ICU admission were retrieved. Results Among 2210 SOT recipients, 154 (6.9%) developed 193 ICU‐acquired infections. Ventilator associated pneumonia was the most frequent (74, 38.3%), followed by bloodstream infections (56, 29%). Multidrug resistant organisms were identified in 34/87 (39%) isolates with available antibiogram. ICU‐acquired infections were associated with significantly higher intra‐ICU mortality (35/154, 22.4% vs. 49/2056, 2.4%; p < 0.001) and longer ICU stays (24 vs. 4 days; p < 0.001). Patients with infections due to multidrug resistant organisms showed higher mortality and length of stay. Conclusions ICU‐acquired infections occurred in nearly 7% of SOT recipients admitted to ICU following a SOT procedure, with a significant contribute of multidrug resistant organisms. These infections were associated with striking differences in mortality and length of stay. Finally, this study suggested that patients with MDRO infections showed trends toward higher mortality and length of stay.
Incidence, microbiology, and mortality of ventilation-associated pneumonia in a large Italian cohort of critically ill patients: results from the PROSAFE project
Marta Colaneri, Giorgia Montrucchio, Giovanni Scaglione, Gianpaola Monti, Giovanni Tricella, Camilla Genovese, Fulvio Agostini, Francesca Dore, Bruno Viaggi, Luca Brazzi, Valentina Sanna, Andrea Gori, Emanuele Palomba, Martina Offer, Stefano Finazzi, Giorgia Montrucchio, Fulvio Agostini, Antonello di Paolo, Angelo Pan, Carla Maria Zotti, Costanza Vicentini, Bruno Viaggi, Gianpaola Monti, Gian Maria Rossolini, Daniela Silengo, Emanuele Russo, Lidia Dalfino, Marta Colaneri
Clinical Microbiology and Infection, 2025
Exploring Human Use of Monoclonal Antibodies Against Critical Bacteria: A Scoping Review of Clinical Trials
Marco Piscaglia, Giovanni Scaglione, Camilla Genovese, Fabio Borgonovo, Fabio Brivio, et al.
Infectious Diseases and Therapy, 2025
INTRODUCTION: The global spread of multidrug-resistant organisms (MDROs), particularly the World Health Organization (WHO) priority pathogens, poses a major challenge to infection treatment, necessitating alternative therapeutic strategies. Monoclonal antibodies (mAbs) have emerged as a potential approach. This review evaluates the clinical efficacy, safety, and limitations of mAbs targeting critical bacterial pathogens, analyzing factors influencing therapeutic outcomes, and proposing strategies to optimize their clinical application. METHODS: A comprehensive analysis of clinical trials investigating antibacterial mAbs was conducted. The review assessed key factors influencing therapeutic outcomes, including trial design, patient heterogeneity, and pharmacokinetics (PK). Comparative analysis was performed to examine differences in efficacy, safety, and limitations across studies. A structured risk of bias assessment was performed using Cochrane Methods' tools. RESULTS: Owing to the low number of studies against MDROs, all trials about mAbs targeting Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA) were included, disregarding resistance profiles. Generally, clinical trials evaluating antibacterial mAbs have shown preliminary evidence. For PA, panobacumab exhibited a favorable safety profile but lacked clear clinical benefits, showing a good survival rate but in a small uncontrolled trial. Rivabazumab reduced bacterial colonization, but did not significantly lower pneumonia incidence. Gremubamab was well tolerated but failed to meet efficacy endpoints. For SA, tosatoxumab and suvratoxumab failed to show statistical significance but may have potential benefits for pneumonia, although phase III trials are needed. CONCLUSIONS: Inconsistent efficacy may stem from complex host-pathogen interactions, biofilm formation, and variations in patient immune status. Future trials should investigate early mAb administration, stratified patient selection, and standardized antibiotic coadministration, poorly addressed thus far. Optimized dosing and mAb combination regimens are promising yet unexplored paths, while high production costs and regulatory issues remain a significant barrier.
Effectiveness of Vascular Catheter Removal Versus Retention in Non-ICU Patients with CRBSI or CABSI in Retrospective, Single-Center Study
Giovanni De Capitani, Marta Colaneri, Claudia Conflitti, Fabio Borgonovo, Lucia Galli, Giovanni Scaglione, Camilla Genovese, Rebecca Fattore, Monica Schiavini, Beatrice Caloni, Daniele Zizzo, Nicola Busatto, Antonio Gidaro, Alba Taino, Maria Calloni, Francesco Casella, Arianna Bartoli, Chiara Cogliati, Emanuele Palomba, Spinello Antinori, Andrea Gori, Antonella Foschi
Microorganisms, 2025
Catheter-associated bloodstream infections (CABSIs) and catheter-related bloodstream infections (CRBSIs) are significant causes of morbidity and mortality worldwide. The current practice favors the removal of vascular access devices (VADs); however, the evidence on this topic remains inconclusive. This study evaluates the clinical outcomes in terms of in-hospital mortality and catheter retention vs. removal in CABSI and CRBSI cases. A retrospective, observational, single-center study was conducted at Luigi Sacco Hospital, Milan, Italy (May 2021–December 2023), and it analyzed non-ICU adult patients with VADs diagnosed with CRBSIs or CABSIs. Clinical and microbiological data were collected to assess the outcomes based on catheter management. Among 1874 patients with VADs, 147 were included, with 164 VAD infection events (92 CABSIs and 72 CRBSIs). Overall, 35 (23.8%) patients with CABSIs and CRBSIs died. Out of those who retained the catheter 19 (35.8%) patients died, while among removal patients 16 (17%) died (p = 0.018). A Candida spp. isolation was found to be significantly associated with a higher likelihood of catheter removal (p = 0.04). Our findings suggest that, in non-ICU CRBSI and CABSI cases, VAD removal may be associated with improved outcomes when feasible.
Corrigendum: Understanding the burden of antibiotic resistance: a decade of carbapenem-resistant Gram-negative bacterial infections in Italian intensive care units (Frontiers in Microbiology, (2024), 15, (1405390), 10.3389/fmicb.2024.1405390)
Giovanni Scaglione, Matilde Perego, Marta Colaneri, Camilla Genovese, Fabio Brivio, Alice Covizzi, Bruno Viaggi, Alessandra Bandera, Andrea Gori, Stefano Finazzi, Emanuele Palomba
Frontiers in Microbiology, 2025
Solid organ transplant in recipients with ongoing SARS-CoV-2 infection: A systematic review of case reports and series
Andrea Lombardi, Marta Colaneri, Cecilia Azzarà, Paola Saltini, Giulia Viero, Emanuele Palomba, Simona Biscarini, Andrea Gori, Alessandra Bandera
International Journal of Infectious Diseases, 2024
Epidemiology, Clinical Manifestations, and Outcome of Mucormycosis in Solid Organ Transplant Recipients: A Systematic Review of Reported Cases
Emanuele Palomba, Marta Colaneri, Cecilia Azzarà, Marco Fava, Angelo Maccaro, Giulia Renisi, Giulia Viero, Harsimran Kaur, Arunaloke Chakrabarti, Andrea Gori, Andrea Lombardi, Alessandra Bandera
Open Forum Infectious Diseases, 2024
Clinical characteristics and outcomes of vaccinated patients hospitalised with SARS-CoV-2 breakthrough infection: Multi-IPV, a multicentre study in Northern Italy
Andrea Lombardi, Simone Villa, Marta Colaneri, Giovanni Scaglione, Francesca Bai, Benedetta Varisco, Valeria Bono, Antonio Vena, Chiara Dentone, Chiara Russo, Mauro Tettamanti, Giulia Renisi, Giulia Viero, Cecilia Azzarà, Marco Mantero, Flora Peyvandi, Matteo Bassetti, Giulia Marchetti, Antonio Muscatello, Alessandro Nobili, Andrea Gori, Alessandra Bandera, Silvano Bosari, Luigia Scudeller, Giuliana Fusetti, Laura Rusconi, Silvia Dell’Orto, Daniele Prati, Luca Valenti, Silvia Giovannelli, Maria Manunta, Giuseppe Lamorte, Francesca Ferarri, Andrea Gori., Alessandra Bandera, Antonio Muscatello, Davide Mangioni, Laura Alagna, Giorgio Bozzi, Andrea Lombardi., Riccardo Ungaro, Giuseppe Ancona, Marco Mussa, Bianca Veronica Mariani, Matteo Bolis, Nathalie Iannotti, Serena Ludovisi, Agnese Comelli, Giulia Renisi, Simona Biscarini, Valeria Castelli, Emanuele Palomba, Marco Fava, Carlo Alberto Peri, Paola Saltini, Giulia Viero, Teresa Itri, Valentina Ferroni, Valeria Pastore, Roberta Massafra, Arianna Liparoti, Toussaint Muheberimana, Alessandro Giommi, Rosaria Bianco, Grazia Eliana Chitani, Chiara Bobbio, Irene De Matteis, Angelo Bianchi Bonomi, Flora Peyvandi, Roberta Gualtierotti, Barbara Ferrari, Raffaella Rossio, Nadia Boasi, Erica Pagliaro, Costanza Massimo, Michele De Caro, Andrea Giachi, Nicola Montano, Barbara Vigone, Chiara Bellocchi, Angelica Carandina, Elisa Fiorelli, Valerie Melli, Eleonora Tobaldini, Francesco Blasi, Stefano Aliberti, Maura Spotti, Leonardo Terranova, Sofia Misuraca, Alice D’Adda, Silvia Della Fiore, Marta Di Pasquale, Marco Mantero., Martina Contarini, Margherita Ori, Letizia Morlacchi, Valeria Rossetti, Andrea Gramegna, Maria Pappalettera, Mirta Cavallini, Agata Buscemi, Marco Vicenzi, Irena Rota, Giorgio Costantino, Monica Solbiati, Ludovico Furlan, Marta Mancarella, Giulia Colombo, Giorgio Colombo, Alice Fanin, Mariele Passarella, Valter Monzani, Ciro Canetta, Angelo Rovellini, Laura Barbetta, Filippo Billi, Christian Folli, Silvia Accordino, Diletta Maira, Cinzia Maria Hu, Irene Motta, Natalia Scaramellini, Anna Ludovica Fracanzani, Rosa Lombardi, Annalisa Cespiati, Matteo Cesari, Tiziano Lucchi, Marco Proietti, Laura Calcaterra, Clara Mandelli, Carlotta Coppola, Arturo Cerizza, Antonio Maria Pesenti, Giacomo Grasselli, Alessandro Galazzi, Alessandro Nobili., Mauro Tettamanti, Igor Monti, Alessia Antonella Galbussera, Ernesto Crisafulli, Domenico Girelli, Alessio Maroccia, Daniele Gabbiani, Fabiana Busti, Alice Vianello, Marta Biondan, Filippo Sartori, Paola Faverio, Alberto Pesci, Stefano Zucchetti, Paolo Bonfanti, Marianna Rossi, Ilaria Beretta, Anna Spolti, Sergio Harari, Davide Elia, Roberto Cassandro, Antonella Caminati, Francesco Cipollone, Maria Teresa Guagnano, Damiano D’Ardes, Ilaria Rossi, Francesca Vezzani, Antonio Spanevello, Francesca Cherubino, Dina Visca, Marco Contoli, Alberto Papi, Luca Morandi, Nicholas Battistini, Guido Luigi Moreo, Pasqualina Iannuzzi, Daniele Fumagalla, Sara Leone
Journal of Infection and Public Health, 2024
New Antibiotics Against Multidrug-Resistant Gram-Negative Bacteria in Liver Transplantation: Clinical Perspectives, Toxicity, and PK/PD Properties
Andrea Lombardi, Laura Alagna, Emanuele Palomba, Giulia Viero, Anna Tonizzo, Davide Mangioni, Alessandra Bandera
Transplant International, 2024
Understanding the burden of antibiotic resistance: a decade of carbapenem-resistant Gram-negative bacterial infections in Italian intensive care units
Giovanni Scaglione, Matilde Perego, Marta Colaneri, Camilla Genovese, Fabio Brivio, Alice Covizzi, Bruno Viaggi, Alessandra Bandera, Andrea Gori, Stefano Finazzi, Emanuele Palomba
Frontiers in Microbiology, 2024
Incidence, microbiological and immunological characteristics of ventilator-associated pneumonia assessed by bronchoalveolar lavage and endotracheal aspirate in a prospective cohort of COVID-19 patients: CoV-AP study
Davide Mangioni, Mauro Panigada, Emanuele Palomba, Chiara Bobbio, Liliane Chatenoud, Laura Alagna, Jacopo Fumagalli, Andrea Gori, Anna Grancini, Amedeo Guzzardella, Andrea Lombardi, Caterina Matinato, Andrea Meli, Antonio Muscatello, Laura Porretti, Mara Tomasello, Elena Trombetta, Luca Valenti, Alessandra Bandera, Giacomo Grasselli
Critical Care, 2023
Perfusion fluid-related infections in liver transplant recipients: A 5-year, single-center, retrospective study
Andrea Lombardi, Giulia Renisi, Daniele Dondossola, Emanuele Palomba, Luca Del Prete, Giulia Viero, Arianna Zefelippo, Cecilia Azzarà, Angelo Maccaro, Carolina Perali, Laura Alagna, Eloisa Franchi, Antonio Muscatello, Andrea Gori, Giacomo Grasselli, Maria Francesca Donato, Caterina Matinato, Lucio Caccamo, Barbara Antonelli, Alessandra Bandera
Transplant Infectious Disease, 2023
Comparison of multiple definitions for ventilator-associated pneumonia in patients requiring mechanical ventilation for non-pulmonary conditions: preliminary data from PULMIVAP, an Italian multi-centre cohort study
L. Alagna, E. Palomba, L. Chatenoud, R. Massafra, F. Magni, L. Mancabelli, S. Donnini, F. Elli, A. Forastieri, G. Gaipa, C. Abbruzzese, R. Fumagalli, M. Munari, A. Panacea, E. Picetti, L. Terranova, F. Turroni, R. Vaschetto, T. Zoerle, G. Citerio, A. Gori, A. Bandera
Journal of Hospital Infection, 2023
Surgical site infections in liver transplantation in the era of multidrug-resistant bacteria
Emilietta BRIGATI, Alessandra BANDERA, Dario CONSONNI, Anna GRANCINI, Umberto MAGGI, Stefania PICONI, Laura ALAGNA, Emanuele PALOMBA, Lucio CACCAMO
Minerva Surgery, 2023
Multidrug-Resistant Bacterial Colonization and Infections in Large Retrospective Cohort of Mechanically Ventilated COVID-19 Patients
Davide Mangioni, Liliane Chatenoud, Jacopo Colombo, Emanuele Palomba, Fernando A. Guerrero, Matteo Bolis, Nicola Bottino, Giuseppe Breda, Maria V. Chiaruttini, Gabriele Fior, Manuela Marotta, Giovanni Massobrio, Caterina Matinato, Antonio Muscatello, Paola Previtali, Sara Santambrogio, Francesca Tardini, Gianluca Zuglian, Giacomo Grasselli, Roberto Fumagalli, Andrea Gori, Nino Stocchetti, Gianpaola Monti, Alessandra Bandera, and
Emerging Infectious Diseases, 2023
Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment with Tixagevimab/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients
Andrea Lombardi, Giulia Viero, Simone Villa, Simona Biscarini, Emanuele Palomba, Cecilia Azzarà, Nathalie Iannotti, Bianca Mariani, Camilla Genovese, Mara Tomasello, Anna Tonizzo, Marco Fava, Antonia Grazia Valzano, Letizia Corinna Morlacchi, Maria Francesca Donato, Giuseppe Castellano, Ramona Cassin, Maria Carrabba, Antonio Muscatello, Andrea Gori, Alessandra Bandera
Biomedicines, 2023
Exploring post-SEPSIS and post-COVID-19 syndromes: crossovers from pathophysiology to therapeutic approach
Darcy Holmes, Marta Colaneri, Emanuele Palomba, Andrea Gori
Frontiers in Medicine, 2023
Gut and airway microbiota dysbiosis and their role in COVID-19 and long-COVID
Giuseppe Ancona, Laura Alagna, Claudia Alteri, Emanuele Palomba, Anna Tonizzo, Andrea Pastena, Antonio Muscatello, Andrea Gori, Alessandra Bandera
Frontiers in Immunology, 2023
The role of immune suppression in COVID-19 hospitalization: clinical and epidemiological trends over three years of SARS-CoV-2 epidemic
Marta Canuti, Maria Cristina Monti, Chiara Bobbio, Antonio Muscatello, Toussaint Muheberimana, Sante Leandro Baldi, Francesco Blasi, Ciro Canetta, Giorgio Costantino, Alessandro Nobili, Flora Peyvandi, Mauro Tettamanti, Simone Villa, Stefano Aliberti, Mario C. Raviglione, Andrea Gori, Alessandra Bandera, and
Frontiers in Medicine, 2023
External validation of risk scores to predict in-hospital mortality in patients hospitalized due to coronavirus disease 2019
Shermarke Hassan, Chava L. Ramspek, Barbara Ferrari, Merel van Diepen, Raffaella Rossio, Rachel Knevel, Vincenzo la Mura, Andrea Artoni, Ida Martinelli, Alessandra Bandera, Alessandro Nobili, Andrea Gori, Francesco Blasi, Ciro Canetta, Nicola Montano, Frits R. Rosendaal, Flora Peyvandi
European Journal of Internal Medicine, 2022
Nocardia Infections in the Immunocompromised Host: A Case Series and Literature Review
Emanuele Palomba, Arianna Liparoti, Anna Tonizzo, Valeria Castelli, Laura Alagna, Giorgio Bozzi, Riccardo Ungaro, Antonio Muscatello, Andrea Gori, Alessandra Bandera
Microorganisms, 2022
Hospital acquired infections in COVID-19 patients in sub intensive care unit: analysis of two waves of admissions
S. Castaldi, P. Perrone, E. Luconi, G. Marano, F. Auxilia, A. Maraschini, Patrizia Bono, L. Alagna, E. Palomba, A. Bandera, P. Boracchi, E. Biganzoli
Acta Biomedica, 2022
Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: comment
Alessandra Bandera, Alessandro Nobili, Mauro Tettamanti, Sergio Harari, Silvano Bosari, Pier Mannuccio Mannucci, Silvano Bosari, Luigia Scudeller, Giuliana Fusetti, Laura Rusconi, Silvia Dell’Orto, Daniele Prati, Luca Valenti, Silvia Giovannelli, Maria Manunta, Giuseppe Lamorte, Francesca Ferrari, Andrea Gori, Alessandra Bandera, Antonio Muscatello, Davide Mangioni, Laura Alagna, Giorgio Bozzi, Andrea Lombardi, Riccardo Ungaro, Giuseppe Ancona, Gianluca Zuglian, Matteo Bolis, Nathalie Iannotti, Serena Ludovisi, Agnese Comelli, Giulia Renisi, Simona Biscarini, Valeria Castelli, Emanuele Palomba, Marco Fava, Valeria Fortina, Carlo Alberto Peri, Paola Saltini, Giulia Viero, Teresa Itri, Valentina Ferroni, Valeria Pastore, Roberta Massafra, Arianna Liparoti, Toussaint Muheberimana, Alessandro Giommi, Rosaria Bianco, Rafaela Montalvao De Azevedo, Grazia Eliana Chitani, Flora Peyvandi, Roberta Gualtierotti, Barbara Ferrari, Raffaella Rossio, Nadia Boasi, Erica Pagliaro, Costanza Massimo, Michele De Caro, Nicola Montano, Barbara Vigone, Chiara Bellocchi, Angelica Carandina, Elisa Fiorelli, Valerie Melli, Eleonora Tobaldini, Francesco Blasi, Stefano Aliberti, Maura Spotti, Leonardo Terranova, Sofia Misuraca, Alice D’Adda, Silvia Della Fiore, Marta Di Pasquale, Marco Mantero Martina Contarini, Margherita Ori, Letizia Morlacchi, Valeria Rossetti, Andrea Gramegna, Maria Pappalettera, Mirta Cavallini, Agata Buscemi, Marco Vicenzi, Irena Rota, Giorgio Costantino, Monica Solbiati, Ludovico Furlan, Marta Mancarella, Giulia Colombo, Giorgio Colombo, Alice Fanin, Mariele Passarella, Valter Monzani, Ciro Canetta, Angelo Rovellini, Laura Barbetta, Filippo Billi, Christian Folli, Silvia Accordino, Diletta Maira, Cinzia Maria Hu, Irene Motta, Natalia Scaramellini, Anna Ludovica Fracanzani, Rosa Lombardi, Annalisa Cespiati, Matteo Cesari, Tiziano Lucchi, Marco Proietti, Laura Calcaterra, Clara Mandelli, Carlotta Coppola, Arturo Cerizza, Antonio Maria Pesenti, Giacomo Grasselli, Alessandro Galazzi, Alessandro Nobili, Mauro Tettamanti, Igor Monti, Alessia Antonella Galbussera, Ernesto Crisafulli, Domenico Girelli, Alessio Maroccia, Daniele Gabbiani, Fabiana Busti, Alice Vianello, Marta Biondan, Filippo Sartori, Paola Faverio, Alberto Pesci, Stefano Zucchetti, Paolo Bonfanti, Marianna Rossi, Ilaria Beretta, Anna Spolti, Sergio Harari, Davide Elia, Roberto Cassandro, Antonella Caminati, Francesco Cipollone, Maria Teresa Guagnano, Damiano D’Ardes, Ilaria Rossi, Francesca Vezzani, Antonio Spanevello, Francesca Cherubino, Dina Visca, Marco Contoli, Alberto Papi, Luca Morandi, Nicholas Battistini, Guido Luigi Moreo, Pasqualina Iannuzzi, Daniele Fumagalli, Sara Leone, and
Internal and Emergency Medicine, 2022
Clinical risk scores for the early prediction of severe outocomes in patients hospitalized for COVID-19: comment
Raffaella Rossio, Mauro Tettamanti, Alessandro Nobili, Sergio Harari, Pier Mannuccio Mannucci, Alessandra Bandera, Flora Peyvandi, Silvano Bosari, Luigia Scudeller, Giuliana Fusetti, Laura Rusconi, Silvia Dell’Orto, Daniele Prati, Luca Valenti, Silvia Giovannelli, Maria Manunta, Giuseppe Lamorte, Francesca Ferrari, Andrea Gori, Alessandra Bandera, Antonio Muscatello, Davide Mangioni, Laura Alagna, Giorgio Bozzi, Andrea Lombardi, Riccardo Ungaro, Giuseppe Ancona, Gianluca Zuglian, Matteo Bolis, Nathalie Iannotti, Serena Ludovisi, Agnese Comelli, Giulia Renisi, Simona Biscarini, Valeria Castelli, Emanuele Palomba, Marco Fava, Valeria Fortina, Carlo Alberto Peri, Paola Saltini, Giulia Viero, Teresa Itri, Valentina Ferroni, Valeria Pastore, Roberta Massafra, Arianna Liparoti, Toussaint Muheberimana, Alessandro Giommi, Rosaria Bianco, Rafaela Montalvao De Azevedo, Grazia Eliana Chitani, Flora Peyvandi, Roberta Gualtierotti, Barbara Ferrari, Raffaella Rossio, Nadia Boasi, Erica Pagliaro, Costanza Massimo, Michele De Caro, Andrea Giachi, Nicola Montano, Barbara Vigone, Chiara Bellocchi, Angelica Carandina, Elisa Fiorelli, Valerie Melli, Eleonora Tobaldini, Francesco Blasi, Stefano Aliberti, Maura Spotti, Leonardo Terranova, Sofia Misuraca, Alice D’Adda, Silvia Della Fiore, Marta Di Pasquale, Marco Mantero, Martina Contarini, Margherita Ori, Letizia Morlacchi, Valeria Rossetti, Andrea Gramegna, Maria Pappalettera, Mirta Cavallini, Agata Buscemi, Marco Vicenzi, Irena Rota, Giorgio Costantino, Monica Solbiati, Ludovico Furlan, Marta Mancarella, Giulia Colombo, Giorgio Colombo, Alice Fanin, Mariele Passarella, Valter Monzani, Ciro Canetta, Angelo Rovellini, Laura Barbetta, Filippo Billi, Christian Folli, Silvia Accordino, Diletta Maira, Cinzia Maria Hu, Irene Motta, Natalia Scaramellini, Anna Ludovica Fracanzani, Rosa Lombardi, Annalisa Cespiati, Matteo Cesari, Tiziano Lucchi, Marco Proietti, Laura Calcaterra, Clara Mandelli, Carlotta Coppola, Arturo Cerizza, Antonio Maria Pesenti, Giacomo Grasselli, Alessandro Galazzi, Alessandro Nobili, Mauro Tettamanti, Igor Monti, Alessia Antonella Galbussera, Ernesto Crisafulli, Domenico Girelli, Alessio Maroccia, Daniele Gabbiani, Fabiana Busti, Alice Vianello, Marta Biondan, Filippo Sartori, Paola Faverio, Alberto Pesci, Stefano Zucchetti, Paolo Bonfanti, Marianna Rossi, Ilaria Beretta, Anna Spolti, Sergio Harari, Davide Elia, Roberto Cassandro, Antonella Caminati, Francesco Cipollone, Maria Teresa Guagnano, Damiano D’Ardes, Ilaria Rossi, Francesca Vezzani, Antonio Spanevello, Francesca Cherubino, Dina Visca, Marco Contoli, Alberto Papi, Luca Morandi, Nicholas Battistini, Guido Luigi Moreo, Pasqualina Iannuzzi, Daniele Fumagalli, Sara Leone, and
Internal and Emergency Medicine, 2022
Antiviral Treatments for Influenza
Emanuele Palomba, Valeria Castelli, Giulia Renisi, Alessandra Bandera, Andrea Lombardi, Andrea Gori
Seminars in Respiratory and Critical Care Medicine, 2021
The Interplay between Gut Microbiota and the Immune System in Liver Transplant Recipients and Its Role in Infections
Giuseppe Ancona, Laura Alagna, Andrea Lombardi, Emanuele Palomba, Valeria Castelli, Giulia Renisi, Daniele Dondossola, Massimo Iavarone, Antonio Muscatello, Andrea Gori, Alessandra Bandera
Infection and Immunity, 2021
Immune checkpoint inhibitors in people living with hiv/aids: Facts and controversies
Valeria Castelli, Andrea Lombardi, Emanuele Palomba, Giorgio Bozzi, Riccardo Ungaro, Laura Alagna, Davide Mangioni, Antonio Muscatello, Alessandra Bandera, Andrea Gori
Cells, 2021
Treatment of SARS-CoV-2 relapse with remdesivir and neutralizing antibodies cocktail in a patient with X-linked agammaglobulinaemia
Emanuele Palomba, Maria Carrabba, Gianluca Zuglian, Laura Alagna, Paola Saltini, Valeria Fortina, Cinzia Hu, Alessandra Bandera, Giovanna Fabio, Andrea Gori, Antonio Muscatello
International Journal of Infectious Diseases, 2021
Congenital Hepatic Fibrosis as a Cause of Recurrent Cholangitis: A Case Report and Review of the Literature
Emanuele Palomba, Marco Maggioni, Giulia Viero, Davide Mangioni, Rosa Lombardi, Barbara Antonelli, Daniele Dondossola, Massimo Iavarone, Anna Ludovica Fracanzani, Alessandra Bandera, Andrea Gori, Andrea Lombardi
Livers, 2021
Mucormycosis in capa, a possible fungal super-infection
Paola Saltini, Emanuele Palomba, Valeria Castelli, Marco Fava, Laura Alagna, Simona Biscarini, Marco Mantero, Francesco Blasi, Anna Grancini, Alessandra Bandera, Andrea Gori, Antonio Muscatello, Andrea Lombardi
Journal of Fungi, 2021
Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study
Giorgio Bozzi, Davide Mangioni, Francesca Minoia, Stefano Aliberti, Giacomo Grasselli, Laura Barbetta, Valeria Castelli, Emanuele Palomba, Laura Alagna, Andrea Lombardi, Riccardo Ungaro, Carlo Agostoni, Marina Baldini, Francesco Blasi, Matteo Cesari, Giorgio Costantino, Anna Ludovica Fracanzani, Nicola Montano, Valter Monzani, Antonio Pesenti, Flora Peyvandi, Marcello Sottocorno, Antonio Muscatello, Giovanni Filocamo, Andrea Gori, Alessandra Bandera
Journal of Allergy and Clinical Immunology, 2021
Early Phases of COVID-19 Are Characterized by a Reduction in Lymphocyte Populations and the Presence of Atypical Monocytes
Andrea Lombardi, Elena Trombetta, Alessandra Cattaneo, Valeria Castelli, Emanuele Palomba, Mario Tirone, Davide Mangioni, Giuseppe Lamorte, Maria Manunta, Daniele Prati, Ferruccio Ceriotti, Roberta Gualtierotti, Giorgio Costantino, Stefano Aliberti, Vittorio Scaravilli, Giacomo Grasselli, Andrea Gori, Laura Porretti, Alessandra Bandera
Frontiers in Immunology, 2020
Characteristics of 1573 healthcare workers who underwent nasopharyngeal swab testing for SARS-CoV-2 in Milan, Lombardy, Italy
A. Lombardi, D. Consonni, M. Carugno, G. Bozzi, D. Mangioni, A. Muscatello, V. Castelli, E. Palomba, A.P. Cantù, F. Ceriotti, B. Tiso, A.C. Pesatori, L. Riboldi, A. Bandera, G. Lunghi, A. Gori
Clinical Microbiology and Infection, 2020
Multidrug‐resistant gram‐negative bacteria decolonization in immunocompromised patients: A focus on fecal microbiota transplantation
Laura Alagna, Emanuele Palomba, Davide Mangioni, Giorgio Bozzi, Andrea Lombardi, Riccardo Ungaro, Valeria Castelli, Daniele Prati, Maurizio Vecchi, Antonio Muscatello, Alessandra Bandera, Andrea Gori
International Journal of Molecular Sciences, 2020

Emanuele Palomba

EDUCATION

RESEARCH, TEACHING, or OTHER INTERESTS

Scopus Publications

RECENT SCHOLAR PUBLICATIONS

MOST CITED SCHOLAR PUBLICATIONS